JUPITER, Fla., Jan. 5, 2016 /PRNewswire/ -- MDNA Life Sciences Inc., a molecular diagnostics company pioneering the development of diagnostic tests based on the mitochondrial genome, announced today that the Company will present at the Biotech Showcase 2016 to be held January 11-13, 2016, at the Parc 55 San Francisco.
MDNA will provide an overview of the company's revenue-generating Prostate Core Mitomic Test™ and its pipeline of blood-based diagnostic tests that are preparing to launch in 2016. In addition, the presentation will discuss the unique benefits of its mitochondrial DNA-based platform for disease screening, diagnosis, prognosis, and monitoring.
|
Event: |
Biotech Showcase 2016 | |
|
Date: |
Tuesday, January 12, 2016 | |
|
Time: |
3:45pm (Pacific Time) | |
|
Location: |
Parc 55 San Francisco, Track E, Room Davidson |
About MDNA Life Sciences
MDNA Life Sciences, Inc., is pioneering the development of molecular diagnostic tests based on the mitochondrial genome. The company's revenue-generating Prostate Core Mitomic Test™ (PCMT™) is the highest performing tissue-based prostate cancer diagnostic on the market with a significantly greater tumor field effect that allows 85% sensitivity and 92% negative predictive value. MDNA is applying its expertise in mitochondrial genomics to developing an extensive and proprietary portfolio of blood-based molecular tests in conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. Blood-based diagnostic tests for prostate cancer and endometriosis are in late stage development. For more information visit www.mdnalifesciences.com.
For further information, please contact:
Tiberend Strategic Advisors, Inc.
Josh Drumm (investors)
jdrumm@tiberend.com; (212) 375-2664
Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686
SOURCE MDNA Life Sciences Inc.